SXTC: China SXT Pharmaceuticals, Inc. Company Value to Net Income

Corporate emblem and logo of China SXT Pharmaceuticals, Inc. (SXTC)

China SXT Pharmaceuticals (SXTC) competes in a fragmented Asian market, leveraging unique raw material purification methods and government contracts. A stable cash flow from the sale of traditional remedies ensures financial resilience despite periodic regulatory inspections. Historical price action with the 0.00 indicator completes the picture, where management focuses on domestic distribution and overcoming bureaucratic barriers during process modernization.

SXTC SXT Pharmaceuticals: Price to Earnings Ratio in the range 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for SXT Pharmaceuticals (SXTC)

- market capitalization information:
Comprehensive company analysis:China SXT Pharmaceuticals, Inc. - SXTC
Flagship merchandise of China SXT Pharmaceuticals, Inc.

Assessing the financial stability of China SXT Pharmaceuticals (SXTC) requires an analysis of the ratio of market capitalization to net income. This coefficient determines the investment payback period, making it possible to identify whether the asset is overvalued or undervalued. By tracking changes in the company's P/E ratio, an investor can balance drawdown risks against growth potential. For this manufacturer of traditional medicines, this indicator confirms the effectiveness of monetizing conservative demand for proven formulas.

Key competitors

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|Market Cap to Net Income Ratio Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Price to Earnings Ratio|Price to Earnings Ratio Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - P/E Multiple|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)